Burton, AR;
Pallett, LJ;
McCoy, LE;
Suveizdyte, K;
Amin, OE;
Swadling, L;
Alberts, E;
... Maini, MK; + view all
(2018)
Circulating and intrahepatic antiviral B cells are defective in hepatitis B.
Journal of Clinical Investigation
, 2018
pp. 1-16.
10.1172/JCI121960.
Preview |
Text
121960.4-20180913202541-covered-253bed37ca4c1ab43d105aefdf7b5536(1).pdf - Published Version Download (6MB) | Preview |
Abstract
B cells are increasingly recognised to play an important role in the ongoing control of hepatitis B virus (HBV). The development of antibodies against the viral surface antigen (HBsAg) constitutes the hallmark of resolution of acute infection and is a therapeutic goal for functional cure of chronic HBV (CHB). We characterised B cells directly ex vivo from the blood and liver of patients with CHB to investigate constraints on their antiviral potential. Unexpectedly, we found that HBsAg-specific B cells persisted in the blood and liver of many patients with CHB and were enriched for T-bet, a signature of antiviral potential in B cells. However purified, differentiated HBsAg-specific B cells from patients with CHB had defective antibody production, consistent with undetectable anti-HBs antibodies in vivo. HBsAg-specific and global B cells had an accumulation of CD21-CD27- atypical memory B cells (atMBC) with high expression of inhibitory receptors including PD-1. These atMBC demonstrated altered signalling, homing, differentiation into antibody-producing cells, survival and antiviral/pro-inflammatory cytokine production, that could be partially rescued by PD-1 blockade. Analysis of B cells within healthy and HBV-infected livers implicated the combination of this tolerogenic niche and HBV infection in driving PD-1hiatMBC and impairing B cell immunity.
Archive Staff Only
 |
View Item |
